OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
7-Point Dermoscopy ChecklistAJCC Melanoma Staging (8th Ed)ALDEN Algorithm (Drug Causality for SJS/TEN)BWH High-Risk SCC StagingBody Surface Area (BSA)Breslow Thickness and Clark LevelDLQIEASI ScoreMSK Melanoma NomogramMelanoma RiskPASI ScorePOEM (Patient-Oriented Eczema Measure)RegiSCAR Criteria for DRESSSCORADSCORTENmPASI (Modified PASI)

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • To predict the probability of sentinel lymph node (SLN) metastasis in clinically node-negative cutaneous melanoma.
  • Aids in shared decision-making regarding whether to perform a Sentinel Lymph Node Biopsy (SLNBx).
CLINICAL INSIGHT

How it Works

Algorithm Variables

  • Age at diagnosis (older age inversely correlates with SLN positivity but directly correlates with poorer survival).
  • Tumor Location (Extremity vs. Trunk vs. Head/Neck).
  • Breslow Thickness (mm).
  • Ulceration (Present/Absent).
  • Mitotic Rate (often integrated into older/updated models of the nomogram).
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • Highly valuable for "borderline" cases (e.g., T1b or thin T2a melanomas) to provide a localized, patient-specific percentage risk rather than generic population guidelines.
  • A threshold of 5-10% predicted risk is typically used to discuss/offer SLNBx.
CLINICAL INSIGHT

Next Steps

Surgical Planning

If predicted risk is high (typically >5%), referral for SLNBx along with wide local excision is standard of care.

CLINICAL INSIGHT

Evidence Base

Primary Reference

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity (Area, Intensity, Symptoms).
0%0%100%

erythema

edema

crusting

excoriation

lichenification

dryness

0010
0010
EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Evaluating the severity of atopic dermatitis (eczema) objectively.
  • Monitoring disease progression and treatment response over time.
  • Standardized reporting in clinical trials for atopic dermatitis therapies.
CLINICAL INSIGHT

How it Works

Formula

Variables

  • A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).
  • B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.
  • C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.
  • It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.
  • A score > 50 indicates severe atopic dermatitis.
CLINICAL INSIGHT

Next Steps

Interpretation

  • < 25: Mild disease.
  • 25 - 50: Moderate disease.
  • > 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.